21 February 2019
Publication
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM.
Stein Schalkwijk, Rob ter Heine, Angela Colbers and David Burger are all members of theme Infectious diseases and global health.
In the Journal of Antimicrobial Chemotherapy Stein Schalkwijk, Rob ter Heine, Angela Colbers and David Burger investigated how pregnant women should be treated with the anti-HIV drug darunavir.
Darunavir is pharmacotherapeutic cornerstone in treatment of HIV. During pregnancy subtherapeutic exposure may occur, leaving a whole new generation at risk for infection with HIV and transmission of drug resistance. Therefore, it was investigated what dosing regimen was most likely to result in therapeutic exposure. It was found that a twice-daily dose of 600 mg, in combination with ritonavir (100 mg) was the best dose during pregnancy.Publication
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.
Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM.
Stein Schalkwijk, Rob ter Heine, Angela Colbers and David Burger are all members of theme Infectious diseases and global health.